We are currently developing three flagship nanoscale technologies
Our Degradome-sensing NanoVehicles (DNVs) deliver chemotherapeutics directly to cancer tumor sites, decreasing the side effects associated with chemotherapy and increasing drug uptake and effectiveness.
Our natural-product based Dental Defense technology prevents the formation of dental plaque before it starts, reducing cavities and gum disease and promoting oral health.
Our novel construct, currently called “Molecule X”, increases the absorption of healthy nutrients in the small intestine; helping those with metabolic disorders get the critical nutrients they need.
Our goal is to improve quality of life through the innovation of nanoscale and genetically engineered biopolymers.
Empire Biotechnologies was formed in 2013 to execute its goal of commercializing platform technologies currently under development at the SUNY College of Nanoscale Science and Engineering and the University of California San Francisco. Our focus is in the area of biopolymer engineering (genetic and nanotech-based) for the design and delivery of novel therapeutics, biosensing and tissue targeting. The co-founders and current management team consists of its Chief Executive Officer, Stephen Kasper, and Chief Technology Officer, Donald McCarthy PhD. This management team is composed of entrepreneurial scientists with extensive training in business entity formation, development, law, and marketing, as well as formal degrees and expertise in biochemistry, molecular biology, nanoscale engineering, cell biology and immunology. Empire Biotechnologies is a member of the iCLEAN incubator, which provides both business assistance and technical support. To date, iCLEAN portfolio companies have raised over $22 million in public and private funding. In 2013, Empire Biotechnologies was awarded first place in the Biotechnology/Healthcare track at the New York Business Plan Competition.